Dana-Farber Research News 03.15.2026 - Summary - MDSpire

Dana-Farber Research News 03.15.2026

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from February 16 - 28.

  • March 15, 2026

  • 21 min

Share

Objective:

Highlight recently published research by Dana-Farber faculty from February 16 - 28, 2026.

Approach:
    Key Findings:
    • Interferon gamma is implicated in mortality for HLH patients.
    • Giant DNA viruses possess a unique translation-initiation complex, indicating evolutionary innovations.
    • Older adults with cancer face significant challenges in treatment and care.
    • Stereotactic radiation significantly improves symptoms compared to whole brain radiation with hippocampal avoidance.
    • Timing of CDK4/6 inhibitors may impact treatment efficacy in advanced breast cancer.
    Interpretation:

    The findings underscore the importance of tailored treatment approaches in various cancer contexts, particularly for vulnerable populations such as older adults.

    Limitations:
    • Limited enrollment of older adults in clinical trials.
    • Variability in patient responses to treatments.
    • Potential biases in retrospective studies.
    Conclusion:

    The research highlights critical advancements in cancer treatment strategies and the need for ongoing support for specific patient demographics.

Original Source(s)

Dana-Farber Research News 03.15.2026

  • March 15, 2026

Related Content

ASCO26: Sara Tolaney, MD, MPH, ASCENT-03

Dana-Farber Cancer Institute's Dr. Sara Tolaney from the ASCENT-03 stud in breast cancer. The data further strengthens the case for approval of sacituzumab govitecan as first-line treatment for patients with advanced triple-negative breast cancer.

  • July 1, 2026

  • 1 min
2026 ASCO Prostate Cancer Highlights

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the prostate cancer clinical updates.

  • July 2, 2026

  • 1 min
ESMO Breast Cancer 2026 Highlights: SERENA-6

Harold Burstein, MD, PhD, and Erica Mayer, MD, MPH discuss results from the SERENA-6 trial, which were presented at the 2026 ESMO Breast Cancer Congress.

  • June 26, 2026

  • 1 min